Expert Point of View: Lisa Carey, MD

Get Permission

Lisa Carey, MD, Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina, Chapel Hill, said the study should not be interpreted as negative for eribulin.

“Most of the patients in this study were being treated second-line. EMBRACE was a totally different circumstance, as it enrolled heavily pretreated patients, and the comparison was eribulin vs whatever the physician still had in his or her grab bag. Here, in [study 301], eribulin was compared to a well-established second-line therapy, and that made a difference,” she noted.

“I am not troubled by the fact that it did not prove superior to capecitabine. The results show instead that eribulin is a reasonable drug. I like having multiple options for my patients,” she said. ■

Disclosure: Dr. Carey reported no potential conflicts of interest.

Related Articles

Primary Endpoint Not Met for Eribulin vs Capecitabine in Breast Cancer

While a global phase III trial failed to meet its primary endpoint in showing an overall or progression-free survival benefit for eribulin (Halavan) in metastatic breast cancer, a trend toward greater efficacy than capecitabine (Xeloda) was observed, researchers reported at the 2012 San Antonio...

SIDEBAR: Treating Earlier with Eribulin

Eribulin is also being evaluated for use earlier in patients with breast cancer, in both the metastatic and adjuvant settings, in three studies described at the San Antonio meeting.

In a phase II study of eribulin as first-line treatment for locally recurrent or metastatic HER2-negative breast...